These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 35116226)

  • 21. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.
    Lamm D; Brausi M; O'Donnell MA; Witjes JA
    Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study.
    Marttila T; Järvinen R; Liukkonen T; Rintala E; Boström P; Seppänen M; Tammela T; Hellström P; Aaltomaa S; Leskinen M; Raitanen M; Kaasinen E;
    Eur Urol; 2016 Aug; 70(2):341-7. PubMed ID: 27085624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bladder contracture: review for intravesical bacillus Calmette-Guerin complication.
    Hameed A; Sezian N; Thwaini A
    Can J Urol; 2007 Dec; 14(6):3745-9. PubMed ID: 18163926
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Abdominal aortic aneurysmal and endovascular device infection with iliopsoas abscess caused by Mycobacterium bovis as a complication of intravesical bacillus Calmette-Guérin therapy.
    Mizoguchi H; Iida O; Dohi T; Tomoda K; Kimura H; Inoue K; Iwata T; Tei K; Miura T
    Ann Vasc Surg; 2013 Nov; 27(8):1186.e1-5. PubMed ID: 23972639
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of immunotherapy in Bacillus Calmette-Guérin unresponsive: non-muscle invasive bladder cancer.
    Suh J; Yoo S
    Transl Cancer Res; 2020 Oct; 9(10):6537-6545. PubMed ID: 35117263
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and Efficacy of Intravesical Bacillus Calmette-Guérin Immunotherapy in Patients with Non-Muscle-Invasive Bladder Cancer Presenting with Asymptomatic Bacteriuria: A Systematic Review.
    Poletajew S; Zapała P; Radziszewski P
    Urol Int; 2017; 99(1):1-5. PubMed ID: 28601885
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS).
    Witjes JA; Palou J; Soloway M; Lamm D; Kamat AM; Brausi M; Persad R; Buckley R; Colombel M; Böhle A
    BJU Int; 2013 Oct; 112(6):742-50. PubMed ID: 23452187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluating the Protective Effect of Intravesical Bacillus Calmette-Guerin against SARS-CoV-2 in Non-Muscle Invasive Bladder Cancer Patients: A Multicenter Observational Trial.
    Hurle R; Soria F; Contieri R; Avolio PP; Mancon S; Lazzeri M; Bernasconi V; Mazzoli S; Pizzuto G; De Bellis M; Rosazza M; Livoti S; Lupia T; Corcione S; Lillaz B; De Rosa FG; Buffi NM; Kamat AM; Gontero P; Casale P
    Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Septic Shock After Intravesical Therapy With Bacillus Calmette-Guerin: A Case Report of a Rare Life-Threatening Complication.
    Fernandes PF; Nunes P; Figueiredo A
    Cureus; 2023 Oct; 15(10):e46563. PubMed ID: 37933342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer.
    Gontero P; Bohle A; Malmstrom PU; O'Donnell MA; Oderda M; Sylvester R; Witjes F
    Eur Urol; 2010 Mar; 57(3):410-29. PubMed ID: 19969411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guérin in patients with high-risk non-muscle-invasive bladder cancer.
    Fujita N; Hatakeyama S; Momota M; Kido K; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
    Urol Oncol; 2020 Aug; 38(8):684.e17-684.e24. PubMed ID: 32278732
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor Efficacy of Bacillus Calmette-Guerin Loaded Cationic Nanoparticles for Intravesical Immunotherapy of Bladder Tumor Induced Rat Model.
    Erdoğar N; Iskit AB; Eroğlu H; Sargon MF; Mungan NA; Bilensoy E
    J Nanosci Nanotechnol; 2015 Dec; 15(12):10156-64. PubMed ID: 26682462
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravesical bacillus Calmette-Guérin instillation in non-muscle-invasive bladder cancer: A review.
    Saluja M; Gilling P
    Int J Urol; 2018 Jan; 25(1):18-24. PubMed ID: 28741703
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
    Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
    J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bacillus Calmette-Guérin treatment of non-muscle invasive bladder cancer.
    Sylvester RJ
    Int J Urol; 2011 Feb; 18(2):113-20. PubMed ID: 21091799
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multisystemic BCGitis: A rare complication of intravesical BCG immunotherapy for bladder cancer.
    Vilares AT; Nunes Silva C; Correia da Silva M; Sousa J; Viamonte B; Madureira AJ
    Radiol Case Rep; 2022 Jul; 17(7):2383-2387. PubMed ID: 35570860
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Spectrum of Complications Induced by Intravesical Immunotherapy of Bacillus Calmette-Guérin for Bladder Cancer.
    Liu Y; Lu J; Huang Y; Ma L
    J Oncol; 2019; 2019():6230409. PubMed ID: 30984262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quadruple immunotherapy of Bacillus Calmette-Guérin, interferon, interleukin-2, and granulocyte-macrophage colony-stimulating factor as salvage therapy for non-muscle-invasive bladder cancer.
    Steinberg RL; Nepple KG; Velaer KN; Thomas LJ; O'Donnell MA
    Urol Oncol; 2017 Dec; 35(12):670.e7-670.e14. PubMed ID: 28801026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bacillus Calmette-Guérin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections.
    Larsen ES; Joensen UN; Poulsen AM; Goletti D; Johansen IS
    APMIS; 2020 Feb; 128(2):92-103. PubMed ID: 31755155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin.
    Sfakianos JP; Kim PH; Hakimi AA; Herr HW
    J Urol; 2014 Feb; 191(2):341-5. PubMed ID: 23973518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.